These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22379455)

  • 1. Multiple sclerosis: pathogenesis and treatment.
    Loma I; Heyman R
    Curr Neuropharmacol; 2011 Sep; 9(3):409-16. PubMed ID: 22379455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.
    Nicholas J; Morgan-Followell B; Pitt D; Racke MK; Boster A
    J Cent Nerv Syst Dis; 2012; 4():81-103. PubMed ID: 23650470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.
    Schreiner TL; Miravalle A
    J Cent Nerv Syst Dis; 2012; 4():1-14. PubMed ID: 23650463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future therapies for multiple sclerosis.
    Minagar A
    Scientifica (Cairo); 2013; 2013():249101. PubMed ID: 24278770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):42-48. PubMed ID: 33976089
    [No Abstract]   [Full Text] [Related]  

  • 7. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary immunomodulatory therapy for multiple sclerosis.
    Rudick RA
    J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.
    Moses H; Brandes DW
    Curr Med Res Opin; 2008 Sep; 24(9):2679-90. PubMed ID: 18694542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
    Hadjigeorgiou GM; Doxani C; Miligkos M; Ziakas P; Bakalos G; Papadimitriou D; Mprotsis T; Grigoriadis N; Zintzaras E
    J Clin Pharm Ther; 2013 Dec; 38(6):433-9. PubMed ID: 23957759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current approved options for treating patients with multiple sclerosis.
    Rizvi SA; Agius MA
    Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
    Galetta SL; Markowitz C; Lee AG
    Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies of glatiramer acetate and interferon beta.
    Goodin D
    Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.